AbbVie antibody drug conjugated Rova-T treatment of small cell lung cancer stage III clinical failure

Based on a pre-planned interim analysis, the Independent Data Monitoring Committee (IDMC) recommended that the MERU study be discontinued because patients receiving Rova-T treatment had no survival benefits compared to the placebo control groupThe results of the MERU study will be presented and/or published in a peer-reviewed medical journal at future medical conferencesRova-T is an experimental antibody drug conjugate (ADC) that targets cancer stem cell-related argon protein 3 (DLL3), which is expressed in more than 80% of tumors in patients with small cell lung cancer (SCLC) and is widely present in tumor cells, including cancer stem cells, but not in normal tissuesRova-T minimizes toxicity to normal cells by delivering a cytotoxic agent directly to cancer cells expressing DLL3 through targeted antibodies"Small cell lung cancer (SCLC) remains one of the most difficult cancers to treat, and there is a significant need for transformative therapies in this area," said Margaret Foley, M.D., global head of physical cancer development atAbbVieWe are disappointed with this result, but remain committed to researching and developing other therapies to change the care of Patients with SCLC and other malignant tumorslooking to the future, AbbVie will continue to focus its research and development efforts on other therapies in research and other oncology portfolios for saleCurrently, abbvie Oncology' portfolio includes more than 300 clinical trials worldwide and more than 20 different tumor types evaluated for the sale and research of drugslung cancer is the leading cause of cancer death, killing nearly 1.8 million people each yearLung cancer is roughly divided into non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC), which accounts for about 15%About two-thirds of SCLC patients are diagnosed with widespread period (ES) disease, i.ethe cancer has spread widely throughout the lungs or to other parts of the bodySCLC is characterized by aggressiveness, rapid growth, early transfer, and is often not discovered until lateChemotherapy (combination or non-use of radiotherapy) has long been the standard first-line treatment, but most patients relapse within a yearThe prognosis of SCLC is poor, with only 6% of patients surviving within five years of diagnosiscancer immunotherapy, a type of cancer treatment that has emerged in recent years, is designed to use the body's own immune system to fight cancer, with PD-(L) 1 checkpoint inhibitors the most popular In terms of lung cancer immunotherapy, Mercadon PD-1 inhibitor Keytruda (Korida, Pablo Pearl Monoantigen) is the absolute dominant player in the NSCLC market Competition in the SCLC market is also growing, with three cancer immunotherapy treatments so far being approved by the U.S FDA for the treatment of SCLC, including: Epdivo (Odivo, August 16, 2018), Roche PD-L1 inhibitor Tecentriq (March 18, 2019), and Mercadon PD-1KeyKey-1 inhibitor Truda (March 16, 2019) Among them, Opdivo and Keytruda received ACCELERATed FDA approval for metastatic SCLC patients who received platinum-containing chemotherapy and at least one other treatment Tecentriq is approved by the FDA to treat adult patients with a wide range of small cell lung cancer (ES-SCLC) with first-line chemotherapy (caplatinum and etopolysine) , AstraZeneca announced in June that it was evaluating the first-line treatment of ES-SCLC for the first-line treatment of EES-SCLC with PD-L1 inhibitor Sypesine and Cacla, which reached the primary endpoint of total survival (OS) ahead of schedule in a pre-planned mid-term analysis: Imfinzi-chemotherapy enabled a statistically significant and clinically significant improvement in OS compared to chemotherapy The data will be presented at an upcoming medical conference AstraZeneca is currently conducting another Phase III study, ADRIATIC, in which SCLC patients receive imfinzi treatment after simultaneous chemotherapy (CCRT) In July, the FDA granted Imfinzi the right to treat SCLC for orphan drugs.